29.62

3.04% -0.93

Castle Biosciences Inc (CSTL)

Overview News Price History Option Chain Financials Why CSTL Down? Discussions Forecast

Castle Biosciences Inc stock is traded at $29.62, with a volume of 264.21K. It is down -3.04% in the last 24 hours and up +28.11% over the past month. Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Previous Close:

$30.55

Open:

$30.93

24h Volume:

264.21K

Relative Volume:

0.65

Market Cap:

$904.88M

Revenue:

$339.92M

Net Income/Loss:

$-12.83M

P/E Ratio:

-68.96

EPS:

-0.4295

Net Cash Flow:

$4.52M

1W Performance:

-7.52%

1M Performance:

+28.11%

6M Performance:

-10.65%

1Y Performance:

+49.45%

1-Day Range:

$29.58

$31.11

1-Week Range:

$29.58

$33.06

52-Week Range:

$17.72

$44.28

Castle Biosciences Inc Stock (CSTL) Company Profile

Name

Castle Biosciences Inc

Sector

Healthcare (1080)

Industry

Diagnostics & Research (50)

Phone

866-788-9007

Address

1500 W. PARKWOOD AVE., FRIENDSWOOD, TX

Employee

942

Twitter

@castlebio

Next Earnings Date

2026-07-30

Latest SEC Filings

CSTL's Discussions on Twitter

Compare CSTL vs TMO, DHR, NTRA, IDXX, A

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CSTL Castle Biosciences Inc	29.62	960.17M	339.92M	-12.83M	4.52M	-0.4295
TMO Thermo Fisher Scientific Inc	588.29	222.96B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	202.45	144.67B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	309.93	45.54B	2.50B	-226.32M	71.51M	-1.6412
IDXX Idexx Laboratories Inc	550.96	44.95B	4.45B	1.10B	1.06B	13.59
A Agilent Technologies Inc	148.53	41.87B	7.23B	1.41B	1.09B	4.979

Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-14-23	Initiated	Guggenheim	Buy
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Jan-07-22	Initiated	Stephens	Overweight
Apr-30-21	Initiated	Lake Street	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Dec-27-19	Reiterated	Canaccord Genuity	Buy
Aug-19-19	Initiated	BTIG Research	Buy
Aug-19-19	Initiated	Canaccord Genuity	Buy
Aug-19-19	Initiated	Robert W. Baird	Outperform
Aug-19-19	Initiated	SVB Leerink	Outperform

View All

Castle Biosciences Inc Stock (CSTL) Latest News

Aug 14, 2026

Is Castle Biosciences Inc (CSTL) a Bargain After 3.0% Drop? GF V - GuruFocus

Aug 14, 2026

CSTL (CSTL) files notice to sell 24,908 common shares on NASDAQ - Stock Titan

Aug 14, 2026

Aug 13, 2026

Wasatch Advisors LP Sells 175,687 Shares of Castle Biosciences, Inc. $CSTL - MarketBeat

Aug 13, 2026

Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction - MarketBeat

Aug 13, 2026

Aug 12, 2026

Castle Biosciences at canaccord growth conference: growth broadens - Investing.com

Aug 12, 2026

Aug 07, 2026